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Human Somatic Mutation Assays As
Biomarkers of Carcinogenesis
by R J. E. Compton,* Kim Hooper,t and Martyn T.
Smith*
lhis paper describes fourassaysthat detect somaticgenemu inhumans: thehypanthine-guin phosphoribosyl
transferase assay, the glycophorin A assay, the HLA-A assay, and the sickle cell hemoglobin assay. Somatic gene muta-
tion can be considered a bionarkerofcarciogenesi, andassays for somatic mutationm y assist epidemiologists in studies
that attempt to identify factors associated with increased risks ofcancer. Practcal aspects ofthe use of these assays are
discussed.
Introduction
Cancer development is a multistep process that may take years
in humans. Critical steps in the process appear to be the produc-
tion of stable changes in the genetic material, called mutations,
and subsequent cell proliferation that produces daughter cells
with mutated DNA.
A number ofmutational events are thought to be necessary to
convert a normal cell into a malignant cancer cell. For example,
sequential mutational changes have been identified in tissues of
the colon that are related to clinical stages in the progression of
colon cancer (1). The development of somatic mutation assays
as biomarkers of the carcinogenic process may, therefore, help
epidemiologists link carcinogenic exposures to cancer outcome
in humans by looking at events early on in the cancer process.
This paper provides an overview ofcurrent human somatic gene
mutation assays and discusses some of the practical aspects in-
volved in their application to epidemiological study populations.
Relationship between Mutation
and Cancer
The lines ofevidence that link somatic mutation with cancer
can be broadly summarized as follows.
a) Cancers often arise in proliferating tissues in contact with
the environment, e.g., the mouth, gut, skin, and lungs (2). In a
tissue in which there is rapid cell proliferation, damage toDNA
may not be completely repaired before cell division occurs. The
damage may then be passed on and made permanent in DNA
strands of the daughter cells.
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b) Many carcinogens bind to or cause mutation in DNA. For
example, benzo[a]pyrene DNA adducts have been detected in
cells exposed to the carcinogen benzo[a]pyrene (3).
c) DNA from tumor cells can "tansform" normal cells. When
DNA from tumor cells was transferred to normal cells, the nor-
mal cells became transformed, i.e., exhibited characteristics of
tumor cells (4).
d) Stable, nonrandom changes in the genetic material are
associated with certain cancers. For example, most cases of
chronic myelogenous leukemia exhibit a characteristic "Phila-
delphia" chromosome, which is the product of a reciprocal
translocation between chromosomes 22 and 9 (5).
e) A tumor probably arises from the clonal expansion of a
single cell, based upon observations of monoclonal X-inacti-
vation patterns in tumors (6).
J) Certain genetic conditions with a high risk ofcancer have
been shown to have defects inDNA repair processes, e.g., ataxia
telangiectasia (7) and Bloom syndrome (8).
Mutation can have consequences other than cancer. Mutation
can cause birth defects or mutations transmitted in the germ line
(9), and it has been implicated in the causation of disease, e.g.,
atherosclerosis (JO). Also, aging may be due to the accumulation
of mutations with the years (11). Biomarkers of mutation may,
therefore, be useful as indicators of effects other than cancer. It
should be remembered, however, that mutation also may have no
effect, since much ofDNA has no known function (12).
Human Mutation Assays
Assays that measure genetic damage in humans can be divid-
ed into two broad categories: assays ofchange at the level ofgross
chromosomal structure and assays of change at the level of the
gene. The DNA in the nucleus is packaged into chromosomes,
which are linear DNA molecules with secondary and tertiary
structure. Genes are short pieces ofDNA that code forRNA and
proteins, and a gene is very small compared to a chromosome:
genes make up approximately 3+% ofa chromosome, and many
genes reside on each chromosome (13).
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Assays of change in chromosome structure include the
chromosome aberration assay, which scores the number ofab-
normal, broken, or missing chromosomes in metaphase cells
(14); the SCE assay, which counts sister chromatid exchanges
(exchanges of identical pieces of chromosomes in duplicated
sister chromatids during cell replication) in metaphase cells (15);
and the micronucleus assay, which measures the fiequency of
micronucleus formation (chromosomes or fragments of
chromosomes lost to the cytoplasm during cell division) (16).
These assays are usually performed in white blood cells (lym-
phocytes). Such assays may reflect damage as well as mutation,
since not all of the events scored reflect a heritable change that
is transmitted from a cell to a daughter cell, the definition of
mutation. This article focuses on human somatic mutation assays
at the level of the gene.
There are practical constraints to measuring gene mutations
in humans. First, the approach must use an accessible tissue. Se-
cond, the method must be able to identify mutant cells and, since
mutation is a rare event, to find and enumerate these cells against
a high background number of normal cells.
Only a small number of human mutation assays have been
developed to date because assays on people must use normal
human genetic material. This is in contrast to the large number
of assays that have been developed in nonhuman species, where
the application oftechniques ofgenetic engineenng or selection
can be used to make detection ofmutants relatively simple. All
ofthe current human mutation assays use blood cells, and all use
a change in or absence ofa normally functioning protein to detect
mutations in the gene coding for the protein.
In using these assays as biomarkers of the carcinogenic pro-
cess, it is preferable to measure changes in genes known to be im-
portant in cancer. Many genes have been identified to date, both
oncogenes (onco- for tumor or mass) which have been shown to
be activated by specific mutation in certain cancers, and antion-
cogenes or tumor-suppressor genes, which have been shown to
be deactivated by mutation (17). Even in the cases where it is
possible to detect a change in these "cancer" genes, however,
there is currently no method for identifying the mutant cells
against the background of normal cells. Identifying cells with
mutations in cancer genes using present technology would re-
quire screening thousands or millions ofcolonies grown from in-
dividual cells, and this is not practical. Current human gene
mutation assays instead screen for mutations that can be easily
identified and selected for by a change or absence of a normal
protein produced by specific genes. The mutation fiequency (and
type) produced in these genes is then used as a surrogate for the
amount and types ofmutations potentially found in cancer genes.
The HPRT Assay
The hypoxanthine-guanine phosphoribosyl transferase (HRPT)
assay was the first human somatic gene mutation assay to be
developed (18-20). This assay identifies and selects (finds against
the background ofnormal cells) mutant cells in one step by tak-
ing advantage ofthe biochemical pathways by which a cell syn-
thesizes DNA.
In cells, DNA is synthesized in two ways, either from nucleo-
tide bases (adenine, dymine, guanine, and cytosine, which make
up the genetic code) made de novo, or from bases recycled from
degraded DNA by the so-called "salvage" pathways. HPRT is
one ofthe enzymes that recycles nucleotide bases. White blood
cells that have mutations at the hprt gene that lead to a nonfunc-
tioning HRPT protein can be detected by adding a toxic analog
(6-thioguanine [6I(]) ofthe nucleotide bases to the cells. Nor-
mal white blood cells incorporate the toxic analog into newly
synthesized DNA, leading to cell death (Fig. La). Mutant cells
that have a nonfunctioning HPRT enzyme do not incorporate the
toxic analog and survive (Fig. Ib). For theHPRT mutation assay,
white blood cells isolated from a human blood sample are
cultured in vitro with the 6TG, and the number ofsurviving mu-
tant cells is determined after a period ofcell growth (1-3 weeks)
by counting the number ofcell colonies. Counting is accomplish-
ed either by an autoradiographic method or a cell cloning
technique.
Mutants can be detected in this assay because only one func-
tional copy ofthe hprt gene is present per cell. Iftwo copies of
the gene were present, the loss of one copy would be hard to
detect, as the other copy would probably supply the missing
function. Only one copy ofthe hprt gene is present because it is
located on the X chromosome, and there is only one active X
chromosome per cell. Humans have 22 pairs ofautosomal (i.e.,
nonsex) chromosomes and one pair of sex chromosomes:
females have twoX chromosomes and males have oneX and one
Y chromosome. Females randomly inactivate one ofthe two X
chromosomes in each cell during development so that females
will have the same amount ofgene product from genes residing
on the X chromosome as do males.
Because only one chromosome carries the functional hprt
gene, the HPRT assay probably does not detect mutations requir-
ing interaction between both chromosomes of a pair. Recent
evidence from cancer biology indicates that chromosome-
chromosome interactions could be an important subclass of
mutations in cancer (17).
Chromosomal-Chromosomal Mutational
Mechanisms in Cancer
Studies ofgenetic change found in several cancers suggest that
chromosome-chromosome mutational mechanisms are of im-
portance in cancer. The first clear evidence came from studies
ofthe disease retinoblastoma, a childhood cancer of the eye. A
prerequisite for formation of the tumor appears to be that both
copies ofa gene (called rb for retinoblastoma, one copy on each
chromosome 13) have been altered and have lost the ability to
produce a protein that suppresses cancer. The rb gene is a
member of the class of recently discovered tumor-suppressor
genes. The children with the hereditary (from a parent or a de
novo germ line mutation) form ofretinoblastoma have one con-
stitutive defective copy ofthis gene, and tumors apparently arise
from the loss of the remaining functional copy of rb during
development (21,22).
In order to determine the molecular mechanisms by which the
functional copy ofrb was lost, the tumorDNA was analyzed by
new molecular techniques. It was found that two general classes
ofmutational events led to the loss ofthe functional rb gene, call-
ed here gene-loss/inactivating and gene-duplicating mutations
(Fig. 2) "Gene-loss/inactivating" mutations refer to changes to
the functional rb gene that eliminate gene function, such as dele-
tion ofpart or all ofthe gene, or point mutations that change the
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FIGURE 1. The HPRT mutation assay selects mutants from T-lymphocytes by exploiting a biochemical pathway ofDNA synthesis. DNA is made from new or
recycled nucleotide bases. HPRT is one of the enzymes in the salvage, or recycling, pathway. In nonmutant cells with functional HPRT enzyme, a toxic analog
ofnucleotide bases (6-thioguanine) is incorporated into DNA, leading to cell death. In mutant cells that lack a functional HPRT enzyme, the toxic analog is not
incorporated, and the cells survive.
base sequence ofDNA. Mutations ofthis type are detected by the
HPRT assay since they require that only one copy ofthe gene be
present. "Gene-duplicating" mutations are those in which the
inherited dysfunctional copy of the gene on the other chromo-
some "replaces" the good copy ofthe gene. Mitotic recombina-
tion or reduplication of the chromosome carrying the dysfunc-
tional gene are gene-duplicating mechanisms, and they have been
demonstrated in many ofthe rb cases (23). Such gene-duplicating
events obviously require that both chromosomes of a pair be
present.
Two recently developed human mutation assays, the gly-
cophorinA assay (GPA) and the HLA-A assays, are able to detect
chromosome-chromosome interactions because the genes
studied are located on autosomal (nonsex) chromosomes. (This
means there are two copies of each gene, one on each of the
paired chromosomes.) Both methods assay for the loss of a
surface protein on cells heterozygous for the gene making the
protein. The cells must be heterozygous because a mutation at
one allele (form of the gene) in a heterozygous cell will lead to
complete loss ofthat form ofthe normal protein product from the
cell. In a homozygous individual, a mutation in one allele would
probably not affect the protein produced by the other allele. Since
mutant cells are detected by the loss of the protein, these cells
would not be detected as mutants.
CONSTITUTIVE I.A FNTINLCPDEFECTIVE COPY FUNCTIONAL COPY(RB-) aROMOS RI (RB)
CHROMOSOME 13
R!-
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e.g. point mutations
RR m RB'
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TUMOR
FiGuRA 2. Mutational mechani generating loss oftumor-suppressor genes
inretinoblastoma. Retinoblastoma apparently arises due to loss ofboth func-
tional copies ofthe rb gene on chromosome 13. Analysis oftumorDNA in-
dicates that two general types of mutational mechanisms, gene loss/inac-
tivating and gene duplicatng, lead to loss ofthe remaining funcional rb gene
in children with a constitutive defective rb gene.
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GPA Assay
The GPA assay measures cells that have lost one form of the
GPA protein present on the surface of red blood cells (23,24).
The gene has two alleles called M and N and is located on
chromosome 4, so a heterozygous individual will have one
chromosome 4 with anM allele oftheGPA gene and one with an
N allele ofthe GPA gene (Fig. 3). Normal red blood cells from
this individual will have bothM and N glycoproteins on their cell
surface. About 50% ofthe population is MN heterozygous, i.e.,
ofMN blood type.
For the GPA mutation assay, red blood cells from a person with
blood typeMN are reacted with anti-glycoprotein antibodies that
can discriminate between the M and N forms of glycoprotein.
The blood cells are first fixed (surface proteins are cross-linked)
to stabilize the cells and prevent agglutination when reacted with
antibodies. The antibodies are labeled with fluorescent mole-
cules-anti-N with green and anti-M with red. Thus, a normal
red blood cell from a person heterozygous for theMN allele will
fluoresce red and green. Blood cells that have suffered a muta-
tion in the GPAM gene that prevents proper expression ofGPA
M on the cell surface will fail to bind antibody to M and will
fluoresce green only (Fig. 3). The antibody-bound cells are
analyzed by a flow cytometer, which measures fluorescence from
all cells and counts the number of green-only mutant cells.
Two classes ofvariant red blood cells can be detected, No and
_ MN
GPA N
NN. N45 cells have the normal amount ofN-GPA on the cell sur-
face and no detectable anti-M antibody binding and presumably
arise from gene-loss/inactivating mutations. NN cells have twice
the normal amount ofN on the cell surface and no M-binding,
and presumably arise from gene-duplicating mutations (Fig. 3).
Finding mutant cells by screening all cells (as opposed to the
HPRT assay where all normal cells are eliminated) is made possi-
ble because flow cytometers can analyze cells very rapidly. In the
GPA assay, fluorescence from each of five million cells can be
measured in 20 min and the mutant cells enumerated.
The GPA assay has the advantage that it can detect chromo-
some-chromosome interactions such as mitotic recombination.
It is limited in that the red blood cell lacks a nucleus, and this
precludes any investigation of mutational mechanisms at the
molecular level. In addition, it cannot be proven that variant cells
are mutant cells, although evidence suggests that this is the case
(24).
HLA-A Assay
The recently developed HLA-A assay (25) is performed on
white blood cells, which contain DNA, and therefore the assay
can be used to provide detailed information on mutational
mechanism. HLA-A is a surface protein found on most nucleated
cells in the body and is involved in the immune response and self
versus nonself discrimination (26). The HLA-A gene is on
0 MfonmdPA > RED aand-MAbFM
* N formo CPA GGREEN * and.N Ab*FM
GREEN
M
MUTANT
GPA N ; GPA 0
GREEN
MUTANT
GPA N GPA N
Bone Marrow Cells
(chromosome #4) Red Blood Cells
FIGURE 3. The GPA assay requires blood samples from persons heterozygous for glycophorin A, a cell surfiace protein on red blood cells. In a normal red blood
precursor tell from a GPA heterozygote, one chromosome ofthe chromosome4paircarries theM form ofGPA and one the N form (left). Mutant cells may arise
from gene-loss/inactivating mutations (called NO) and gene-duplicating mutations (called NN) (left). The right portion ofthe figure shows a normal heterozygous
red blood cell with bothM andN blood group proteins on the cell surface, and mutant cells with normal (NO) or twicenormal (NN) amounts ofN GPA, but which
lack normalM GPA. Normal and mutant cells are reacted with anti-GPAM and anti-GPAN antibodies labeled with fluorescent molecules, anti-M with red and
anti-N with green. Fluorescence ofeach cell is measured by flow cytometry, and the number ofgreen-only muta, bothN and NN, is detemined for each samwle.
_*"~ NN
138
HUMlANSOMATICMUTATIONASSAYS
chromosome 6 and is one ofthe most polymorphic loci known,
which means that most people are heterozygous for the HLA-A
protein, i.e., have more than one form on their cells.
The HLA-A human somatic mutation assay is similar to the
GPA assay in that mutants are detected by lack of antibody bin-
ding to a cell surface protein. In order to detect mutants, however,
normal cells are eliminated as in the HPRT assay, rather than
counted as in the GPA assay.
To determine HLA-A mutant frequencies for an individual,
white blood cells are isolated from a blood sample and typed with
HLA-A antibodies. The assay currently works on individuals
heterozygous for A2 or A3 forms (alleles) ofHLA-A. More than
60% ofan average population is heterozygous for one or the other
of these alleles. Blood from an A2Ax or A3Ax blood type in-
dividual (x = other allele) is incubated with the A2 or A3 an-
tibody, and the cells are treated with complement. Complement
is a complex of serum proteins that is part ofthe body's natural
immune defenses and acts to kill antibody-covered cells. The ad-
dition of complement, therefore, kills the normal A2 or A3
antibody-covered cells, and mutant cells with altered or missing
HLA-A protein fail to bind the antibody and survive (Fig. 4). The
cells are plated, and the surviving cells are grown into clones,
which are counted to obtain a mutant frequency after correcting
for growth on nonselected plates. The clones can then be analyz-
ed to characterize the nature ofthe mutation in the cell. In a sam-
ple ofnormal individuals, mitotic recombination was responsi-
ble for an average of one-third of the mutations observed (27).
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FIGURE 4. The HLA-A assay requires blood samples from subjects hetero-
zygous atthe HLA-A gene, a gene with many alleles. In the current assay, sub-
jects must be heterozygous for A2 or A3, i.e., A2Ax or A3Ax, where Ax =
other HLA-A allele. The assay measures mutant T-lymphocytes that lack a
normal A2 or A3 protein due to mutation at the HLA-A gene. To identify
mutants, T-lymphocytes are reacted with anti-HLA-A-A2 or -A3 antibody.
Normal cells bind antibody and are killed by the addition ofcomplement (C'),
which targets antibody-bound cells. Mutant cells do not bind antibody and
survive. The assay detects gene-loss/inactivating mutants and gene-dupli-
cating mutants, shown at the lower left.
Hb-S and Other Assays
A fourth human somatic mutation assay, Hb-S, detects the pro-
duction of a mutant form of hemoglobin (Hb-S) caused by a
specific point mutation in one ofthe Hb genes (28-30). Hb-S is
the hemoglobin responsible for sickle cell anemia. Fluorescently
labeled antibodies for the mutated Hb are added to blood
preparations fixed on a slide. The slide is then scanned by
microscopy (automated image analysis) to detect anti-Hb-S an-
tibody binding (28). This assay detects only one specific muta-
tion, a change ofthe base adenine to thymine. The assay therefore
does not detect a wide range of mutational mechanisms and so
has a much lower mutant frequency than is observed in either the
HPRT, GPA, or HLA-A assays. However, modifications are be-
ing introduced that will increase the number of mutations
detected (28).
Other assays that are currently under development look at
changes in the DNA directly rather than using a cellular protein
selection process (31). Such assays hold promise for the future
because they could be performed on many more tissue types, as
they do not require cell growth and do not require the gene pro-
duct to be expressed. This could allow the detection ofmutations
in tissues thought to be directly targeted by a certain exposure.
Current somatic mutation assays are all performed on one tissue,
the blood, and there are uncertainties inherent in extrapolating
from mutations in a nontarget tissue to mutations in a target
tissue. DNA assays also have the potential to be used on stored
samples. In addition, the bias inherent in the phenotype selection
approach (which detects only mutations that produce an altered
protein) would be eliminated, since these assays would be able
to detect mutations even ifthey did not lead to an altered protein.
Practical Considerations in Using
These Assays in Epidemiological
Studies
Two biologic characteristics of cells used in any assay, their
lifespan and location in the body, affect the sensitivity ofthe assay
to the mutagenic effects ofa specific exposure. The HLA-A and
HPRT assays use white blood cells, specifically T-lymphocytes,
which have a lifetime ofseveral years (usually estimated as 1-4+
years) and so can accumulate HLA-A mutations over this time
period. TheGPA and Hb-S assays detect red blood cell mutants
whose mutagenic events occurred in progenitor cells in the bone
marrow, either in the differentiating cells or in the stem cells that
give rise to all blood cells. For mutagenic events occurring in the
differentiating cell pool, a red blood cell assay can detect effects
ofexposures occurring no more than to 4 to 5 months previous-
ly, as the lifespan ofthemame erythrocyte is 120 days. Stem cells
are long-lived, and stem cell mutants will persist for the lifetime
of an individual, as demonstrated by the high GPA mutant fre-
quencies remaining in atomic bomb survivors > 40 years after
radiation exposure (32).
Location ofthe cells in the body also affects assay sensitivity.
TheGPA andHb assays measure mutations in the bone marrow
compartnent only, and mutagens must penetrate to this compart-
ment to be detected. The HLA-A and HPRT assays record
mutants in T-cells in the circulating blood, so these assays may
be sensitive to a wider variety of mutagens.
Practical matters ofassay protocol may limit sensitivity. White
blood cell (T-lymphocyte) assays require 10 to 20 mL ofblood,
139
140 COMPIONETAL
andthecellsstdertestmustbeisolatedfromfreshlydrawn, sterile
blood. Theseassays requirecellgrowth, and lOto20days elapse
before a mutant frequency canbe obtained. In contrast, the GPA
assay is rapid(2 days) andrequires < 1 mLofblood, whichdoes
not have to be sterile and can be analyzed for up to 2 weeks if
refrigerated. IntheHb-S assay, slidescanbestoredat-20C for
atleast5 months (28). TheGPAandHLA-Aassayscanbeapplied
only topersonsofcertainbloodtypes, whereastheHPRTandHb-
S assays can be used on all subjects, which may be an issue ifthe
size ofa study populations is limited.
TheHPRTassay hasbeenthemostwidely applied to date, and
intrmation has been developed on age as a risk factor in a sam-
ple population, on radiation and chemotherapy-exposed patients,
on smokers versus nonsmokers, and on persons with cancer-
prone syndromes (17-19,33-56). TheGPA assay has been applied
to radiation and chemotherapy-exposed individuals, persons
with occupational exposures to styrene, persons with cancer-
prone syndromes, and a limited general population
(23,24,32,57-63). The HLA-A assay has been applied to the
study of the effects of age and to chemotherapy-exposed in-
dividuals (25,27,64,65). The Hb-S assay has been applied to a
small number of subjects with different mutagenic exposures
(28) and with cancer-prone syndromes.
Further studies are required to supply epidemiologists with
more information on the following subjects. a) Major risk fac-
tors for these assays, which can be confounders in a study, need
to be determined. Age has been identified as a risk factor in the
GPA and HLA-A assays, and both age and smoking are risk fac-
tors in the HPRT assay. b) The range of values for these assays
among individuals in the general population (interindividual
variability) needs to be characterized, as does the variation in
assay values for given individuals over time (intra-individual
variation). Some of this information is available for the HPRT
assay (40). Subpopulations with extremely high or low assay
values could help to identify important risk factors. c) The rela-
tion between the rate and tpes ofsomatic mutation measured in
these and future assays needs to be determined relative to prior
mutagenic exposures and relative to prospective risk ofclinical
disease. Issues such as the relation between mutations in the
tissue measured and mutations in target tissues and the validity
ofusing noncancer genes as surrogates for cancer genes need to
be examined in such studies.
If further information can be collected, current and future
assays ofsomatic mutation in humans show promise for a range
ofepidemiological studies: investigating cancer clusters; iden-
tifying occupational cohorts at risk; providing dose-response
data for risk assessment; monitoring potentially harmful effects
ofclinical tatments (e.g., chemotherapy); and, tirough the use
of intervention studies, identfying exposures that are mutgenic,
and possibly carcinogenic, to humans.
This vork was s by NIH grant P42ES04705, the Diecors Fund frm
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